Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients

Who May Qualify: - 1\. 18 - 65 years old; - 2.Chronic hepatitis B patients with clear diagnosis of hematology, etiology and clinical (for example: HBsAg positive for more than 6 months); - 3\. In virologically suppressed (HBV DNA below the lower detection limit) CHB patients by NAs treatment, HBsAg decreased by less than 0.5log in the last 6 months of Peg-IFNα therapy, and then discontinued Peg-IFNα at least 6 months; - 4.Patients with HBV DNA negative, HBeAg negative, HBsAg quantification ≤ 200IU/ml at Peg-IFNα discontinuation and enrollment. Who Should NOT Join This Trial: - 1\. Cirrhosis; - 2.platelet count \< 90×109/L, WBC count \< 3.0×109/L, neutrophil count \< 1.3×109/L, ALT \> ULN (40U/L), total bilirubin \> 2ULN; - 3.History of or suspicion of hepatocellular carcinoma - 4.Patients received immunosuppressive therapy or other therapy influenced study within 12 months; - 5.Hepatitis A, hepatitis C, hepatitis D, HIV infection or other active infections; - 6.Alcohol or drug abuse/dependence; - 7.Investigator judges that the participants are not suitable for this study. Always talk to your doctor about whether this trial is right for you.